Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection is a research paper published in Vaccines (2020). On theSindex it has a DataRank of 0. It has been cited 8 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 1R21 AI139733
National Institutes of Health
Grant: 1R21AI113514
U.S. Department of Defense
Grant: HDTRA1-14-CHEM-BIO-BAA
National Institutes of Health
Grant: 5R21AI113514-02
An Adjuvant-Independent Dual-Targeted (Multi-Function) Mucosal Vaccine Platform
National Institutes of Health
Grant: 1R21AI139733-01
Development of an adjuvant-free mucosal vaccine platform via sequential FcRn-mediated transepithelial Ag transport to the NALT and Fc RI-enhanced Ag processing and presentation within the NALT.
FWCI
0.68
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals